Zai Lab's (09688) stock surged 7.3% during Wednesday's intraday trading, reflecting strong investor optimism following the company's strategic updates at the 44th Annual JPMorgan Healthcare Conference.

The biopharmaceutical firm highlighted its oncology pipeline, including Zocilurtatug pelitecan (Zoci), which could become its first globally launched oncology product. Three pivotal studies targeting small cell lung cancer and neuroendocrine carcinoma are planned by end-2026. Additionally, Zai Lab emphasized its diversified commercial portfolio, with Enobosarm Trichloride Capsules slated for launch in H1 2026 and other products like povetacicept nearing commercialization.

These developments underscore Zai Lab's potential to expand its global footprint and revenue streams, driving the stock's upward movement.